Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet
Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program
You may also be interested in...
Pfizer agreed to pay $250m up front for worldwide rights to a Phase II drug that could target a broad population in cardiovascular disease. Scrip talked to Pfizer's head of internal medicine research about it.
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.